Strides Considers Sputnik Light Production

US Filing For GLP Analog In Dec

Strides will consider making RDIF’s Sputnik Light vaccine after filling orders for Sputnik V, which it expects to launch in October. The COVID-19 portfolio is being expanded and the Indian company is set to make a Para IV filing for a diabetes product in December, CEO R Ananthanarayanan tells Scrip.

Business Strategy Concept
Strides Formulating Its COVID-19 Business Strategy • Source: Alamy

Strides Pharma Science Limited’s CEO and managing director R Ananthanarayanan might not have bargained for the turbulence his company has been through since he joined. But he has handled it with the dexterity of a seasoned professional as his years of experience at Cipla Limited and other former employers kicked in.

As he took the helm at Strides Pharma, ranitidine, a key contributor to revenues, came under regulatory glare due to...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip